孟鲁司特钠对AECOPD患者MMP-9和TIMP-1水平的影响

The effect of montelukast sodiumr on serum MMP-9 and TIMP-1 levels in acute exacerbations of chronic obstructive pulmonary disease

目的通过采用酶联免疫吸附试验（ELISA）法测定中重度慢性阻塞性肺疾病急性加重期（acute exacerbations of chronic obstructive pulmonary disease，AECOPD）患者治疗前、后血清基质金属蛋白酶-9（matrixmetalloproteinase-9，MMP-9）和基质金属蛋白酶组织抑制剂-1（tissue inhibitor of metalloproteinases-1，TIMP-1）水平，观察孟鲁司特钠对中重度AECOPD患者血清MMP-9、TIMP-1水平的影响。方法选取中重度AECOPD患者63例为研究对象，随机分组：治疗组30例，给予常规治疗＋孟鲁司特钠10mg，1次／d，口服，疗程7～14d；对照组33例，给予常规治疗，疗程7～14d。采用双抗体夹心酶联免疫吸附法测定两组血清MMP-9和TIMP-1水平，并对其变化进行分析比较。结果①治疗组和对照组治疗前MMP-9水平比较差异无统计学意义，治疗组治疗后MMP-9水平[（22．02±6．34）μg／L]低于对照组治疗后[（26．31±8．23）μg／L]（P〈O．05）。治疗组和对照组治疗前MMP-9水平分别为[（27．59士7．71）μg／L]、[（27．74±7．96）μg／L]均高于治疗后E（22．02±6．34）,ug／L]、[（26．31±8．23）μg／L]（P〈0．05）。②治疗组和对照组治疗前TIMP-1水平比较差异无统计学意义，治疗组治疗后[（22．23±5．52）μg／L]TIMP-1水平高于对照组治疗后[（17．23±8．23）μg／L]（P〈O．05）。治疗组和对照组治疗前TIMP-1水平均分别为[（16．34±1．45）~g／L]、[（16．20±2．03）μg／L]低于治疗后[（22．23±5．52）μg／L]、[（17．23±2．45）μg／L]（P〈0．05）。结论孟鲁司特钠对中重度AECOPD患者血清MMP-9和TIMP-1水平有影响，推测孟鲁司特钠可减轻中重度AECOPD患者气道炎症并延缓气道重塑。

Objective Serum of matrix metalloproteinases-1 （TIMP-1） levels moderate metalloproteinase-9 （MMP-9） and tissue inhibitor of and severe acute exacerbations of chronic obstructive pulmonary disease （AECOPD） patients before and after treatment were tested using ELISA to observe the effect of montelukast modiumr on serum MMP-9 and TIMP-1 levels. Methods Sixty-three cases mild moderate and severe AECOPD were selected that were randomly divided into 30 cases as treatment group and 33 cases as control group. The treatment group were given conventional therapy plus montelukast sodium （10 mg oral treatment once-daily for 7-14 days）. The control group were given conventional therapy for 7-14 days. Serum of MMP-9 and TIMP-1 levels in moderate and severe AECOPD patients before and aIter treatment were tested using ELISA and compared with its changes. Results （2）Before the treatment,the comparison of MMP-9 serum level between the treatment group and control group has no significant difference （ P 〈 0.05）. While the serum level in treatment group [（22.02 ± 6.34）μg/L] is higher than the control group after the treatment [（26.31_±8.23）μg/L-]（ P 〈0.05）. The serum level in the treatment group [（27.59 ± 7.71） /lg/L] and control group [（27.74 ± 7.96）μg/L] is respectively higher than group after the treatment [ （22.02 ±6.34）μg/L], [ （26.31 ± 8.23 ）μg/L] （ P 〈 0.05）. （1） Serum level of TIMP-1 before the treatment has no significant difference between the treatment group and control group（ P （0.05）. Though the serum level after the treatment is different between these two groups [（22. 23±5.52）μg/L],[（17.23±8.23） 9g/L,respectively]（ P （0.05）. The serum level in the treatment group [（16.34±1.45） μg/L] and control group [-（16.20!2.03） μg/L] is respectively higher than group after the treatment [（22.23± 5.52） μg/L, （I7.23 ± 2.45） μg/L, respectively] （ P 〈0.05）. Conclusions Montelukast sodiumr do have an effect on serum level of MMP-9 and TIMP-1 in AECOPD, which seems that montelukast sodiumr may alleviate the inflammation in air flue and delay the airway remodeling.